{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:41:11Z","timestamp":1778964071692,"version":"3.51.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosc"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00406-007-1006-x","type":"journal-article","created":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T05:04:27Z","timestamp":1205557467000},"page":"28-47","source":"Crossref","is-referenced-by-count":64,"title":["Pharmacogenomics and therapeutic prospects in dementia"],"prefix":"10.1007","volume":"258","author":[{"given":"Ram\u00f3n","family":"Cacabelos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,16]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051238","volume":"2","author":"J Aerssens","year":"2001","unstructured":"Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W (2001) APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2:69\u201377","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000051232","volume":"12","author":"O Almkvist","year":"2001","unstructured":"Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A (2001) Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 12:22\u201332","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1358\/mf.1999.21.8.794835","volume":"21","author":"XA Alvarez","year":"1999","unstructured":"Alvarez XA, Mouzo R, Pichel V et al (1999) Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Methods Find Exp Clin Pharmacol 21:633\u2013644","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1006_CR4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/mf.2000.22.4.584453","volume":"22","author":"XA Alvarez","year":"2000","unstructured":"Alvarez XA, Pichel V, P\u00e9rez PA et al (2000) Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Methods Find Exp Clin Pharmacol 22:585\u2013594","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00129785-200101010-00001","volume":"1","author":"MJ Arranz","year":"2001","unstructured":"Arranz MJ, Collier D, Kerwin RW (2001) Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 1:3\u201310","journal-title":"Am J Pharmacogenomics"},{"key":"1006_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00008571-199902000-00005","volume":"9","author":"A Atkinson","year":"1999","unstructured":"Atkinson A, Singleton AB, Steward A et al (1999) CYP2D6 is associated with Parkinson\u2019s disease but not with dementia with Lewy bodies or Alzheimer\u2019s disease. Pharmacogenetics 9:31\u201335","journal-title":"Pharmacogenetics"},{"key":"1006_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.55.091902.104426","volume":"55","author":"CP Austin","year":"2004","unstructured":"Austin CP (2004) The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 55:1\u201313","journal-title":"Annu Rev Med"},{"key":"1006_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(97)00624-1","volume":"233","author":"F Bellivier","year":"1997","unstructured":"Bellivier F, Laplanche JL, Schurhoff F et al (1997) Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett 233:45\u201348","journal-title":"Neurosci Lett"},{"key":"1006_CR9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2165\/00023210-200317130-00002","volume":"17","author":"D Bentue-Ferrer","year":"2003","unstructured":"Bentue-Ferrer D, Tribut O, Polard E, Allain H (2003) Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17:947\u2013963","journal-title":"CNS Drugs"},{"key":"1006_CR10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00008571-199910000-00013","volume":"9","author":"ML Bernal","year":"1999","unstructured":"Bernal ML, Sinues B, Johansson I et al (1999) Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9:657\u2013660","journal-title":"Pharmacogenetics"},{"key":"1006_CR11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","volume":"11","author":"S Bernard","year":"2006","unstructured":"Bernard S, Neville KA, Nguyen AT, Flockhart DA (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 11:126\u2013135","journal-title":"Oncologist"},{"key":"1006_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000087371","volume":"20","author":"A Bizzarro","year":"2005","unstructured":"Bizzarro A, Marra C, Acciarri A et al (2005) Apolipoprotein E epsilon-4 allele differentiates the clinical response to donepezil in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 20:254\u2013261","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(02)00013-5","volume":"12","author":"B Borroni","year":"2002","unstructured":"Borroni B, Colciaghi F, Pastorino L et al (2002) ApoE genotype influences the biological effects of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 12:195\u2013200","journal-title":"Eur Neuropsychopharmacol"},{"key":"1006_CR14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1389557023406458","volume":"2","author":"R Cacabelos","year":"2002","unstructured":"Cacabelos R (2002) Pharmacogenomics in Alzheimer\u2019s disease. Mini Rev Med Chem 2:59\u201384","journal-title":"Mini Rev Med Chem"},{"key":"1006_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/078538902320772115","volume":"34","author":"R Cacabelos","year":"2002","unstructured":"Cacabelos R (2002) Pharmacogenomics for the treatment of dementia. Ann Med 34:357\u2013379","journal-title":"Ann Med"},{"key":"1006_CR16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/phgs.4.5.597.23795","volume":"4","author":"R Cacabelos","year":"2003","unstructured":"Cacabelos R (2003) The application of functional genomics to Alzheimer\u2019s disease. Pharmacogenomics 4:597\u2013621","journal-title":"Pharmacogenomics"},{"key":"1006_CR17","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1517\/14656566.6.12.1967","volume":"6","author":"R Cacabelos","year":"2005","unstructured":"Cacabelos R (2005) Pharmacogenomics and therapeutic prospects in Alzheimer\u2019s disease. Exp Opin Pharmacother 6:1967\u20131987","journal-title":"Exp Opin Pharmacother"},{"key":"1006_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/1745509X.1.2.303","volume":"1","author":"R Cacabelos","year":"2005","unstructured":"Cacabelos R (2005) Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer\u2019s disease. Aging Health 1:303\u2013348","journal-title":"Aging Health"},{"issue":"Suppl B","key":"1006_CR19","first-page":"1","volume":"29","author":"R Cacabelos","year":"2007","unstructured":"Cacabelos R (2007) Molecular pathology and pharmacogenomics in Alzheimer\u2019s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Methods Find Exp Clin Pharmacol 29(Suppl B):1\u201391","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1006_CR20","first-page":"303","volume":"3","author":"R Cacabelos","year":"2007","unstructured":"Cacabelos R (2007) Donepezil in Alzheimer\u2019s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 3:303\u2013333","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl","key":"1006_CR21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0404.2000.00302.x","volume":"176","author":"R Cacabelos","year":"2000","unstructured":"Cacabelos R, Alvarez A, Fern\u00e1ndez-Novoa L, Lombardi VRM (2000) A pharmacogenomic approach to Alzheimer\u2019s disease. Acta Neurol Scand 176(Suppl):12\u201319","journal-title":"Acta Neurol Scand"},{"key":"1006_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1358\/dot.2000.36.7.589153","volume":"36","author":"R Cacabelos","year":"2000","unstructured":"Cacabelos R, Alvarez XA, Lombardi V et al (2000) Pharmacological treatment of Alzheimer disease: from phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 36:415\u2013499","journal-title":"Drugs Today"},{"key":"1006_CR23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1179\/016164104225017677","volume":"26","author":"R Cacabelos","year":"2004","unstructured":"Cacabelos R, Fern\u00e1ndez-Novoa L, Corzo L et al (2004) Phenotypic profiles and functional genomics in dementia with a vascular component. Neurol Res 26:459\u2013480","journal-title":"Neurol Res"},{"issue":"Suppl A","key":"1006_CR24","first-page":"1","volume":"27","author":"R Cacabelos","year":"2005","unstructured":"Cacabelos R, Fern\u00e1ndez-Novoa L, Lombardi V, Kubota Y, Takeda M (2005) Molecular genetics of Alzheimer\u2019s disease and aging. Methods Find Exp Clin Pharmacol 27(Suppl A):1\u2013573","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1006_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000078531","volume-title":"Molecular neurobiology of Alzheimer Disease and related disorders","author":"R Cacabelos","year":"2004","unstructured":"Cacabelos R, Fern\u00e1ndez-Novoa L, Pichel V, Lombardi V, Kubota Y, Takeda M (2004) Pharmacogenomic studies with a combination therapy in Alzheimer\u2019s disease. In: Takeda M, Tanaka T, Cacabelos R (eds) Molecular neurobiology of Alzheimer Disease and related disorders. Karger, Basel, pp 94\u2013107"},{"key":"1006_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1201\/b14441-12","volume-title":"Recent progress in Alzheimer\u2019s and Parkinson\u2019s Disease","author":"R Cacabelos","year":"2005","unstructured":"Cacabelos R, Kubota Y, Isaza C et al (2005) Functional genomics and pharmacogenetics in Alzheimer\u2019s disease. In: Hanin I, Cacabelos R, Fisher A (eds) Recent progress in Alzheimer\u2019s and Parkinson\u2019s Disease. Taylor & Francis, London, pp 89\u2013102"},{"key":"1006_CR27","unstructured":"Cacabelos R (2007) Pleiotropic effects of APOE in dementia: influence on functional genomics and pharmacogenetics. In: Fisher A, Hanin I, Stocchi F, Memo M (eds) Advances in Alzheimer\u2019s and Parkinson\u2019s disease. Insights, progress, and perspectives. Springer, Secaucus (NJ) (in press)"},{"issue":"Suppl 4","key":"1006_CR28","first-page":"S27","volume":"11","author":"R Cacabelos","year":"1997","unstructured":"Cacabelos R, Rodr\u00edguez B, Carrera C, Beyer K, Lao JI, Sellers MA (1997) Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis Assoc Disord 11(Suppl 4):S27\u2013S37","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl B","key":"1006_CR29","first-page":"5","volume":"31","author":"R Cacabelos","year":"2006","unstructured":"Cacabelos R, Takeda M (2006) Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer\u2019s disease. Drugs Future 31(Suppl B):5\u2013146","journal-title":"Drugs Future"},{"key":"1006_CR30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0006-3223(98)00060-2","volume":"45","author":"JA Cervilla","year":"1999","unstructured":"Cervilla JA, Russ C, Holmes C et al (1999) CYP2D6 polymorphisms in Alzheimer\u2019s disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification. Biol Psychiatry 45:426\u2013429","journal-title":"Biol Psychiatry"},{"key":"1006_CR31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.410380415","volume":"38","author":"X Chen","year":"1995","unstructured":"Chen X, Xia Y, Alford M et al (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer\u2019s disease. Ann Neurol 38:653\u2013658","journal-title":"Ann Neurol"},{"key":"1006_CR32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000082887","volume":"19","author":"D Craig","year":"2005","unstructured":"Craig D, Hart DJ, McIlroy SP, Passmore AP (2005) Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 19:154\u2013157","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00002512-200623100-00005","volume":"23","author":"SS Egger","year":"2006","unstructured":"Egger SS, Bachmann A, Hubmann N, Schlienger RG, Kr\u00e4henb\u00fchl S (2006) Prevalence of potentially inappropriate medication use in elderly patients. Comparison between general medicine and geriatric wards. Drugs Aging 23:823\u2013837","journal-title":"Drugs Aging"},{"key":"1006_CR34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/qjmed\/93.7.391","volume":"93","author":"G Emilien","year":"2000","unstructured":"Emilien G, Ponchon M, Caldas C, Isacson O, Maloteux JM (2000) Impact of genomics on drug discovery and clinical medicine. QJ Med 93:391\u2013423","journal-title":"QJ Med"},{"key":"1006_CR35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans WE, McLeod HL (2003) Pharmacogenomics\u2014drug disposition, drug targets, and side effects. N Engl J Med 348:538\u2013549","journal-title":"N Engl J Med"},{"key":"1006_CR36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2004-6313","volume":"6","author":"L Flicker","year":"2004","unstructured":"Flicker L, Martins RN, Thomas J et al (2004) Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men. J Alzheimer Dis 6:329\u2013336","journal-title":"J Alzheimer Dis"},{"key":"1006_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1440-1819.2001.00793.x","volume":"55","author":"T Furuno","year":"2001","unstructured":"Furuno T, Kawanishi C, Iseki E et al (2001) No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies. Psychiatry Clin Neurosci 55:89\u201392","journal-title":"Psychiatry Clin Neurosci"},{"key":"1006_CR38","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000066020","volume":"14","author":"T Gabryelewicz","year":"2002","unstructured":"Gabryelewicz T, Religa D, Styczynska M et al (2002) Behavioural pathology in Alzheimer\u2019s disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord 14:208\u2013212","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","volume":"59","author":"EA Gaikovitch","year":"2003","unstructured":"Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59:303\u2013312","journal-title":"Eur J Clin Pharmacol"},{"key":"1006_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1201\/b14486-19","volume-title":"The Brain Cholinergic System in health and disease","author":"E Giacobini","year":"2006","unstructured":"Giacobini E (2006) Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer\u2019s disease, related disorders. In: Giacobini E, Pepeu G (eds) The Brain Cholinergic System in health and disease. Informa Healthcare, Oxon, pp 235\u2013264"},{"key":"1006_CR41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1132814","volume":"314","author":"M Goedert","year":"2006","unstructured":"Goedert M, Spillantini MG (2006) A century of Alzheimer\u2019s disease. Science 314:777\u2013781","journal-title":"Science"},{"key":"1006_CR42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrg1229","volume":"4","author":"DB Goldstein","year":"2003","unstructured":"Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet 4:937\u2013947","journal-title":"Nat Rev Genet"},{"key":"1006_CR43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00008571-199802000-00003","volume":"8","author":"E-U Griese","year":"1998","unstructured":"Griese E-U, Zanger UM, Brudermanns U et al (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15\u201326","journal-title":"Pharmacogenetics"},{"key":"1006_CR44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1389200013338513","volume":"2","author":"E Hedlund","year":"2001","unstructured":"Hedlund E, Gustafsson JA, Warner M (2001) Cytochrome P450 in the brain: a review. Curr Drug Metabol 2:245\u2013263","journal-title":"Curr Drug Metabol"},{"key":"1006_CR45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1192\/bjp.186.3.197","volume":"186","author":"I Hickie","year":"2005","unstructured":"Hickie I, Naismith S, Ward PB et al (2005) Reduced hippocapal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 186:197\u2013202","journal-title":"Br J Psychiatry"},{"key":"1006_CR46","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1474-4422(04)00883-X","volume":"3","author":"DB Hogan","year":"2004","unstructured":"Hogan DB, Goldlist B, Naglie G, Patterson C (2004) Comparison studies of cholinesterase inhibitors for Alzheimer\u2019s disease. Lancet Neurol 3:622\u2013628","journal-title":"Lancet Neurol"},{"key":"1006_CR47","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1532-5415.2006.00854.x","volume":"54","author":"P Hollingworth","year":"2006","unstructured":"Hollingworth P, Hamshire ML, Moskvina V et al (2006) Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer\u2019s disease. J Am Geriatr Soc 54:1348\u20131354","journal-title":"J Am Geriatr Soc"},{"key":"1006_CR48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrg1578","volume":"6","author":"DJ Hunter","year":"2005","unstructured":"Hunter DJ (2005) Gene\u2013environment interactions in human diseases. Nat Rev Genet 6:287\u2013298","journal-title":"Nat Rev Genet"},{"key":"1006_CR49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature03001","volume":"431","author":"International Human Genome Sequencing Consortium","year":"2004","unstructured":"International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome. Nature 431:931\u2013945","journal-title":"Nature"},{"key":"1006_CR50","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1358\/mf.2000.22.9.802286","volume":"22","author":"CA Isaza","year":"2000","unstructured":"Isaza CA, Henao J, L\u00f3pez AM, Cacabelos R (2000) Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 22:695\u2013705","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1006_CR51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1192\/bjp.185.2.102","volume":"185","author":"JM Kim","year":"2004","unstructured":"Kim JM, Stewart R, Shin IS, Yoon JS (2004) Vascular\/risk and late-life depression in a Korean community population. Br J Psychiatry 185:102\u2013107","journal-title":"Br J Psychiatry"},{"key":"1006_CR52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrn1604","volume":"6","author":"JM Levenson","year":"2005","unstructured":"Levenson JM, Sweatt JD (2005) Epigenetic mechanisms in memory formation. Nat Rev Neurosci 6:108\u2013118","journal-title":"Nat Rev Neurosci"},{"key":"1006_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10010","volume":"10","author":"E Loveman","year":"2006","unstructured":"Loveman E, Green C, Kirby J et al (2006) The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer\u2019s disease. Health Technol Assess 10:1\u2013176","journal-title":"Health Technol Assess"},{"key":"1006_CR54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2","volume":"13","author":"SH MacGowan","year":"1998","unstructured":"MacGowan SH, Wilcock GK, Scott M (1998) Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 13:625\u2013630","journal-title":"Int J Geriatr Psychiatry"},{"key":"1006_CR55","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrg1428","volume":"5","author":"UA Meyer","year":"2004","unstructured":"Meyer UA (2004) Pharmacogenetics\u2014five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669\u2013676","journal-title":"Nat Rev Genet"},{"key":"1006_CR56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/DMR-120023681","volume":"35","author":"T Mizutani","year":"2003","unstructured":"Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35:99\u2013106","journal-title":"Drug Metab Rev"},{"key":"1006_CR57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000064926","volume":"14","author":"T Muller-Thomsen","year":"2002","unstructured":"Muller-Thomsen T, Artl S, Ganzer S et al (2002) Depression in Alzheimer\u2019s disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men. Dement Geriatr Cogn Disord 14:59\u201363","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR58","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1176\/appi.ajp.159.12.2096","volume":"159","author":"S Naismith","year":"2002","unstructured":"Naismith S, Hickie I, Ward PB et al (2002) Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry 159:2096\u20132098","journal-title":"Am J Psychiatry"},{"key":"1006_CR59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1176\/appi.ajp.158.6.878","volume":"158","author":"RD Nebes","year":"2001","unstructured":"Nebes RD, Vora IJ, Meltzer CC et al (2001) Relationship of deep white matter hyperintensities and apolipoprotein E genotype to depressive symptoms in older adults without clinical depression. Am J Psychiatry 158:878\u2013884","journal-title":"Am J Psychiatry"},{"key":"1006_CR60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/ng1593","volume":"37","author":"AC Need","year":"2005","unstructured":"Need AC, Motulsky AG, Goldstein DB (2005) Priorities and standards in pharmacogenetic research. Nat Genet 37:671\u2013681","journal-title":"Nat Genet"},{"key":"1006_CR61","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1212\/WNL.53.7.1415","volume":"53","author":"DJ Nicholl","year":"1999","unstructured":"Nicholl DJ, Bennett P, Hiller L et al (1999) A study of five candidate genes in Parkinson\u2019s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 53:1415\u20131421","journal-title":"Neurology"},{"key":"1006_CR62","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1176\/appi.ajp.161.11.2081","volume":"161","author":"JT O\u2019Brien","year":"2004","unstructured":"O\u2019Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N (2004) A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 161:2081\u20132090","journal-title":"Am J Psychiatry"},{"key":"1006_CR63","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379\u20132388","journal-title":"N Engl J Med"},{"key":"1006_CR64","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nrd1749","volume":"4","author":"KA Philips","year":"2005","unstructured":"Philips KA, Van Bebber SL (2005) Measuring the value of pharmacogenomics. Nat Rev Drug Discov 4:500\u2013509","journal-title":"Nat Rev Drug Discov"},{"key":"1006_CR65","first-page":"147","volume":"24","author":"J Poirier","year":"1999","unstructured":"Poirier J (1999) Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer\u2019s disease. J Psychiatry Neurosci 24:147\u2013153","journal-title":"J Psychiatry Neurosci"},{"key":"1006_CR66","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1073\/pnas.92.26.12260","volume":"92","author":"J Poirier","year":"1995","unstructured":"Poirier J, Delisle M-C, Quirion R et al (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92:12260\u201312264","journal-title":"Proc Natl Acad Sci USA"},{"key":"1006_CR67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00008571-200010000-00001","volume":"10","author":"S Raimundo","year":"2000","unstructured":"Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger (2000) Elucidation of the genetic basis of the common intermediate metabolizer phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577\u2013581","journal-title":"Pharmacogenetics"},{"key":"1006_CR68","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261\u20132268","journal-title":"Neurology"},{"key":"1006_CR69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00365510500469702","volume":"66","author":"JO Rasmussen","year":"2006","unstructured":"Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA (2006) CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 66:129\u2013136","journal-title":"Scand J Clin Lab Invest"},{"key":"1006_CR70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1468-1331.2000.00073.x","volume":"7","author":"AS Rigaud","year":"2000","unstructured":"Rigaud AS, Traykov L, Caputo L et al (2000) The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer\u2019s disease. Eur J Neurol 7:255\u2013258","journal-title":"Eur J Neurol"},{"key":"1006_CR71","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008571-200207000-00009","volume":"12","author":"AS Rigaud","year":"2002","unstructured":"Rigaud AS, Traykov L, Latour F et al (2002) Presence of absence of least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer\u2019s disease. Pharmacogenetics 12:415\u2013420","journal-title":"Pharmacogenetics"},{"key":"1006_CR72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JF et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics 6:246\u2013254","journal-title":"Pharmacogenomics"},{"key":"1006_CR73","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","volume":"5","author":"AD Roses","year":"2004","unstructured":"Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645\u2013656","journal-title":"Nat Rev Genet"},{"key":"1006_CR74","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284\u2013295","journal-title":"Am J Hum Genet"},{"key":"1006_CR75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10038-003-0021-7","volume":"48","author":"S Saito","year":"2003","unstructured":"Saito S, Ishida A, Sekine A et al (2003) Catalog of 680 variants among eight cytochrome P450 (CYP) genes: nine esterase genes, and two other genes in the Japanese population. J Hum Genet 48:249\u2013270","journal-title":"J Hum Genet"},{"key":"1006_CR76","first-page":"85","volume":"1502","author":"AM Saunders","year":"2000","unstructured":"Saunders AM, Trowers MK, Shimkets RA et al (2000) The role of apolipoprotein E in Alzheimer\u2019s disease: pharmacogenomic target selection. Biochem Biophys Acta 1502:85\u201394","journal-title":"Biochem Biophys Acta"},{"key":"1006_CR77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/pr.56.2.1","volume":"56","author":"EG Schuetz","year":"2004","unstructured":"Schuetz EG, Relling MV, Kishi S et al (2004) PharGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 56:159","journal-title":"Pharmacol Rev"},{"key":"1006_CR78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.phrs.2005.10.005","volume":"53","author":"MG Scordo","year":"2006","unstructured":"Scordo MG, Dahl ML, Spina E, Cordici F, Arena MG (2006) No association between CYP2D6 polymorphisms and Alzheimer\u2019s disease in an Italian population. Pharmacol Res 53:162\u2013165","journal-title":"Pharmacol Res"},{"key":"1006_CR79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.genom.3.022502.103022","volume":"3","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ, Podlisny MB (2002) Deciphering the genetic basis of Alzheimer\u2019s disease. Annu Rev Genomics Hum Genet 3:67\u201399","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1006_CR80","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","volume":"293","author":"KM Sink","year":"2005","unstructured":"Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 293:596\u2013608","journal-title":"JAMA"},{"key":"1006_CR81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s007020170066","volume":"108","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Hesse C, Basun H et al (2001) Tacrine and rate of progression in Alzheimer\u2019s disease\u2014relation to ApoE allele genotype. J Neural Transm 108:451\u2013458","journal-title":"J Neural Transm"},{"key":"1006_CR82","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S0033291702007201","volume":"33","author":"DC Steffens","year":"2003","unstructured":"Steffens DC, Norton MC, Hart AD et al (2003) Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. Psychol Med 33:541\u2013547","journal-title":"Psychol Med"},{"key":"1006_CR83","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/gps.1567","volume":"21","author":"M Steinberg","year":"2006","unstructured":"Steinberg M, Corcoran C, Tschanz JT et al (2006) Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 21:824\u2013830","journal-title":"Int J Geriatr Psychiatry"},{"key":"1006_CR84","first-page":"469","volume":"54","author":"Y-H Suh","year":"2002","unstructured":"Suh Y-H, Checler F (2002) Amyloid precursor protein, presenilins, and \u03b1-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer\u2019s disease. Phamacol Rev 54:469\u2013525","journal-title":"Phamacol Rev"},{"key":"1006_CR85","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.tins.2004.08.005","volume":"27","author":"B Teter","year":"2004","unstructured":"Teter B, Finch CE (2004) Caliban\u2019s heritance and the genetics of neuronal aging. Trends Neurosci 27:627\u2013632","journal-title":"Trends Neurosci"},{"key":"1006_CR86","first-page":"152","volume":"8","author":"O Tribut","year":"2002","unstructured":"Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D (2002) Pharmacogenomics. Med Sci Monit 8:152\u2013163","journal-title":"Med Sci Monit"},{"key":"1006_CR87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000096682","volume":"23","author":"Flier Wm Van der","year":"2006","unstructured":"Van der Flier Wm, Staekenborg S, Pijnenburg YA et al (2006) Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23:42\u20136","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1006_CR88","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd2075","volume":"5","author":"D Dam Van","year":"2006","unstructured":"Van Dam D, De Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956\u2013970","journal-title":"Nat Rev Drug Discov"},{"key":"1006_CR89","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","volume":"62","author":"F Varsaldi","year":"2006","unstructured":"Varsaldi F, Miglio G, Scordo MG et al (2006) Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer\u2019s disease patients. Eur J Clin Pharmacol 62:721\u2013726","journal-title":"Eur J Clin Pharmacol"},{"key":"1006_CR90","first-page":"99","volume":"27","author":"NM Verrils","year":"2006","unstructured":"Verrils NM (2006) Clinical proteomics: present and future prospects. Clin Biochem Rev 27:99\u2013116","journal-title":"Clin Biochem Rev"},{"key":"1006_CR91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.genom.6.080604.162315","volume":"7","author":"RM Weinshilboum","year":"2006","unstructured":"Weinshilboum RM, Wang L (2006) Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 7:223\u2013245","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1006_CR92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1440-1819.2001.00877.x","volume":"55","author":"SI Woo","year":"2001","unstructured":"Woo SI, Kim JW, Seo HG et al (2001) CYP2D6*4 polymorphism is not associated with Parkinson\u2019s disease and has no protective role against Alzheimer\u2019s disease in the Korean population. Psychiatry Clin Neurosci 55:373\u2013377","journal-title":"Psychiatry Clin Neurosci"},{"key":"1006_CR93","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/342260","volume":"71","author":"SP Wooding","year":"2002","unstructured":"Wooding SP, Watkins WS, Bamshad MJ et al (2002) DNA sequence variations in a 3.7-kb noncoding sequence 5-prime of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 71:528\u2013542","journal-title":"Am J Hum Genet"},{"key":"1006_CR94","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","volume":"41","author":"HG Xie","year":"2001","unstructured":"Xie HG, Kim RB, Wood AJ, Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol 41:815\u2013850","journal-title":"Annu Rev Pharm Toxicol"},{"key":"1006_CR95","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","volume":"54","author":"HG Xie","year":"2002","unstructured":"Xie HG, Prasad HG, Kim RB, Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257\u20131270","journal-title":"Adv Drug Deliv Rev"},{"key":"1006_CR96","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00002093-199809000-00013","volume":"12","author":"H Yamada","year":"1998","unstructured":"Yamada H, Dahl ML, Viitanen M, Winblad B, Sjoqvist F, Lannfelt L (1998) No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Dis Assoc Disord 12:204\u2013207","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1006_CR97","unstructured":"http:\/\/www.icgeb.org\/"},{"key":"1006_CR98","unstructured":"http:\/\/www.imm.ki.se\/CYPalleles\/cyp2d6.htm"},{"key":"1006_CR99","unstructured":"http:\/\/www.mitomap.org\/"},{"key":"1006_CR100","unstructured":"http:\/\/www.molgen.ua.ac.be\/ADMutations\/"},{"key":"1006_CR101","unstructured":"http:\/\/www.ncbi.nlm.nih.gov\/OMIM"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-007-1006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-007-1006-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-007-1006-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:11:22Z","timestamp":1708719082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-007-1006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":101,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1007\/s00406-007-1006-x","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}